Effect of L-dopa on plasma homocysteine in PD patients: Relationship to B-vitamin status

Neurology

Volumn 60, Issue 7, 2003, Pages 1125-1129

  Miller, J W ^a,c   Selhub, J ^a   Nadeau, M R ^a   Thomas, C A ^b   Feldman, R G ^b   Wolf, P A ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYANOCOBALAMIN; DOPAMINE RECEPTOR STIMULATING AGENT; FOLIC ACID; HOMOCYSTEINE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PERGOLIDE; PERGOLIDE MESILATE; PROFENAMINE; PYRIDOXAL 5 PHOSPHATE; PYRIDOXINE; SELEGELINE; SELEGILINE; SYMMETRAL; TRIHEXYPHENIDYL; VITAMIN B GROUP;

ADULT; AGED; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; AMINO ACID SYNTHESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLIC ACID BLOOD LEVEL; FOLIC ACID DEFICIENCY; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; NUTRITIONAL REQUIREMENT; PARKINSON DISEASE; PRIORITY JOURNAL; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 0037426415     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000055899.24594.8E     Document Type: Article

References (46)

1. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998;49:31-62.
2. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland P-M. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998;55:1449-1455.
3. Nilsson K, Gustafson L, Faldt R, et al. Hyperhomocystinemia - a common finding in a psychogeriatric population. Eur J Clin Invest 1996;26:853-859.
4. Joosten E, Lesaffre E, Riezler R, et al. Is metabolic evidence for vitamin-B12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? J Gerontol 1997;52:M76-M79.
5. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-483.
6. Miller JW, Green R, Mungas DM, Reed BR, Jagust WJ. Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology 2002;58:1471-1475.
7. Bell IR, Edman JS, Selhub J, et al. Plasma homocysteine in vascular disease and in nonvascular dementia of depressed elderly people. Acta Psychiatr Scand 1992;86:386-890.
8. Riggs KM, Spiro A, Tucker K, Rush D. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr 1996;63:306-314.
9. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998;13:235-239.
10. Lehmann M, Gottfries CG, Regland B. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dementia Geriatr Cogn Disord 1999;10:12-20.
11. Nilsson K, Gustafson L, Hultberg B. The plasma homocysteine concentration is better than that of serum methylmalonic acid as a marker for sociopsychological performance in a psychogeriatric population. Clin Chem 2000;46:691-696.
12. Budge M, Johnston C, Hogervorst E, et al. Plasma total homocysteine and cognitive performance in a volunteer elderly population. Ann NY Acad Sci 2000;903:407-410.
13. Morris MS, Jacques PF, Rosenberg IH, Selhub J. Hyperhomocystinemia associated with poor recall in the Third National Health and Nutrition Examination Survey. Am J Clin Nutr 2001;73:927-933.
14. Duthie SJ, Whalley LJ, Collins AR, Leaper S, Berger K, Deary IJ. Homocysteine, B vitamin status, and cognitive function in the elderly. Am J Clin Nutr 2002;75:908-913.
15. Kalmijn S, Launer LJ, Lindemans J, Bots ML, Hofman A, Breteler MM. Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. Am J Epidemiol 1999;150:283-289.
16. Ravaglia G, Forti P, Maioli F, et al. Blood homocysteine and vitamin B levels are not associated with cognitive skills in healthy normally ageing subjects. J Nutr Health Aging 2000;4:218-222.
17. Selhub J, Miller JW. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 1992;55:131-138.
18. Daly D, Miller JW, Nadeau MR, Selhub J. The effect of L-dopa administration and folate deficiency on plasma homocysteine concentrations in rats. J Nutr Biochem 1997;8:634-640.
19. Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA. Effect of L-dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol 1997;20:55-66.
20. Chalmers JP, Baldessarini RJ, Wurtman RJ. Effects of L-dopa on norepinephrine metabolism in the brain. Proc Natl Acad Sci USA 1971;68:662-666.
21. Ordonez LA, Wurtman RJ. Methylation of exogenous 3,4-dihydroxyphenylalanine (L-dopa) - effects on methyl group metabolism. Biochem Pharmacol 1973;22:134-137.
22. Ordonez LA, Wurtman RJ. Folic acid deficiency and methyl group metabolism in rat brain: effects of L-dopa. Arch Biochem Biophys 1974;160:372-376.
23. Taylor KM, Randall PK. Depletion of S-adenosyl-L-methionine in mouse brain by antidepressive drugs. J Pharmacol Exp Ther 1975;194:303-310.
24. Fuller RW, Hemrick-Luecke SK, Perry KW. Effects of L-dopa on epinephrine concentration in rat brain: possible role of inhibition of norepinephrine N-methyltransferase by S-adenosylhomocysteine. J Pharmacol Exp Ther 1982;223:84-89.
25. Fuller RW, Perry KW, Hemrick-Luecke SK. Tropolone antagonism of the L-dopa-induced elevation of S-adenosylhomocysteine: S-adenosylmethionine ratio but not depletion of adrenaline in rat hypothalamus. J Pharm Pharmacol 1984;36:419-420.
26. Wagner J, Danzin C, Huot-Olivier S, Claverie N, Palfreyman MG. High-performance liquid chromatographic analysis of S-adenosylmethionine and its metabolites in rat tissues: interrelationship with changes in biogenic catechol levels following treatment with L-dopa. J Chromatogr 1984;290:247-262.
27. Taufek HR, Bone AH. Influence of exogenous L-3,4-dihydroxyphenylalanine (L-dopa) on the methionine and S-adenosylmethionine concentrations in the brain and other tissues. Biochem Soc Trans 1980;8:62-63.
28. Allain P, Le Bouil A, Cordillet E, Le Quay L, Bagheri H, Montastruc JL. Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicology 1995;16:527-529.
29. Kuhn W, Roebroek R, Blom H, et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol 1998;40:225-227.
30. Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Muller T. Hyperhomocystinemia in Parkinson's disease. J Neurol 1998;245:811-812.
31. Blandini F, Fancellu R, Martignoni E, et al. Plasma homocysteine and L-DOPA metabolism in patients with Parkinson disease. Clin Chem 2001;47:1102-1104.
32. Muller T, Werne B, Fowler B, Kuhn W. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet 1999;354:126-127.
33. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 2000;55:437-440.
34. Vester B, Rasmussen K. High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem 1991;29:549-554.
35. Horne DW, Patterson D. Lactobacillus casei microbiological assay of folic acid derivatives in 96-well microtiter plates. Clin Chem 1988;34:2357-2359.
36. Tamura T, Freeberg LE, Cornwell PE. Inhibition by EDTA of growth of Lactobacillus casei in folate microbiological assay and its reversal by added manganese or iron. Clin Chem 1990;36:1993.
37. Camp VM, Chipponi J, Faraj BA. Radioenzymatic assay for direct measurement of pyridoxal-5′-phosphate. Clin Chem 1983;29:642-644.
38. Miller JW, Nadeau MR, Smith D, Selhub J. Vitamin B6 deficiency vs folate deficiency: comparison of responses to methionine loading in rats. Am J Clin Nutr 1994;59:1033-1039.
39. Schott HF, Clark WG. Dopa decarboxylase inhibition through the interaction of coenzyme and substrate. J Biol Chem 1952;196:449-462.
40. Pfeiffer R, Ebadi M. On the mechanism of the nullification of CNS effects of L-dopa by pyridoxine in parkinsonian patients. J Neurochem 1972;19:2175-2181.
41. Kott E, Bornstein B, Eichhorn F. Excretion of dopa metabolites. N Engl J Med 1971;284:395.
42. Kurtz DJ, Kanfer JN. L-Dopa: effect on cerebral pyridoxal phosphate content and coenzyme activity. J Neurochem 1971;18:2235-2236.
43. Korten A, Lodder J, Vreeling F, Boreas A, van Raak L, Kessels F. Stroke and idiopathic Parkinson's disease: does shortage of dopamine offer protection against stroke? Mov Disord 2001;16:119-123.
44. Waters CH. Managing the late complications of Parkinson's disease. Neurology 1997;49(suppl 1):S49-S57.
45. Bernstein AL. Vitamin B6 in clinical neurology. Ann NY Acad Sci 1990;585:250-260.
46. National Research Council. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Washington, DC: National Academy Press, 1998.